AstraZeneca and MSD's Lynparza (Olaparib) Receives the CHMP's Positive Opinion as 1L Maintenance Treatment for HRD-Positive Advanced Ovarian Cancer
Shots:
- The CHMP has recommended the approval of Lynparza + bevacizumab for the 1L maintenance treatment of patients with HRD+ advanced ovarian cancer. The positive opinion is based on a biomarker subgroup analysis of P-III PAOLA-1 study
- The P-III PAOLA-1 study involves assessing of Lynparza + bevacizumab vs bevacizumab as monothx. for newly diagnosed advanced FIGO Stage III-IV high-grade serous/ endometroid ovarian- fallopian tube- or peritoneal cancer patients who had a complete or partial response to 1L treatment with Pt. based CT and bevacizumab
- The study resulted in 67% reduction the risk of disease progression or death- improved PFS (37.2 vs 17.7 mos.). Further results of PAOLA-1 trial demonstrated improvement in the time to second disease progression- PFS2 (50.3 vs 35.3 mos.)- presented at ESMO 2020
Ref: AstraZeneca | Image: New Europe
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com